Cite
Leblanc S, Roux J, Tillaut H, et al. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Rev Neurol (Paris). 2021;177(10):1250-1261doi: 10.1016/j.neurol.2021.04.006.
Leblanc, S., Roux, J., Tillaut, H., Le Page, E., & Leray, E. (2021). Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Revue neurologique, 177(10), 1250-1261. https://doi.org/10.1016/j.neurol.2021.04.006
Leblanc, S, et al. "Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study." Revue neurologique vol. 177,10 (2021): 1250-1261. doi: https://doi.org/10.1016/j.neurol.2021.04.006
Leblanc S, Roux J, Tillaut H, Le Page E, Leray E. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Rev Neurol (Paris). 2021 Dec;177(10):1250-1261. doi: 10.1016/j.neurol.2021.04.006. Epub 2021 Jul 10. PMID: 34253346.
Copy
Download .nbib